About 18.5% of patients with moderate to severe ulcerative colitis experienced remission after taking tofacitinib for eight weeks, compared with 8.2% of patients taking a placebo, researchers reported in The New England Journal of Medicine. In another trial, remission was experienced after one year by 34.3% of patients taking a 5-mg dose of tofacitinib and 40.6% of patients taking a 10-mg dose, compared with 11.1% of the placebo group.